Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsIrving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
Estimating the term…
Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
A method of treating an individual human for immunodepletion of EGFR-expressing squamous cell carcinoma of the head and neck (HSNCC) cells in which an activating mutation in one or more of KRAS, NRAS and BRAF is present, the method comprising:
A method of targeting EGFR-expressing squamous cell carcinoma of the head and neck (HSNCC) cells comprising an activating mutation in KRAS for immunodepletion, the method comprising:
A method of assessing an EGFR-expressing squamous cell carcinoma of the head and neck (HSNCC) for responsiveness to a combination of (i) a dose of 1 mg/kg of an antibody that binds to CD47 and blockades CD47 activity;
Dependencies are inferred from the claim text.